Stay updated on Flotetuzumab in PIF/ER AML Clinical Trial

Sign up to get notified when there's something new on the Flotetuzumab in PIF/ER AML Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Flotetuzumab in PIF/ER AML Clinical Trial page

  1. Check
    7 days ago
    Change Detected
    Summary
    The page now displays the ClinicalTrials.gov record for the flotetuzumab AML study, including study design, participant criteria, locations, and posted results. The record indicates the trial was terminated for a business decision and is no longer seeking participants.
    Difference
    97%
    Check dated 2026-11-08T12:18:07.000Z thumbnail image
  2. Check
    14 days ago
    Change Detected
    Summary
    The footer revision label changes from v3.7.2 to v3.8.0 while the study page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-01T12:28:35.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    A notice was added announcing an NIH website transition and stating that “Super Intelligence” (SI) is being used in place of “Artificial Intelligence” (AI) during the transition.
    Difference
    1%
    Check dated 2026-10-25T12:52:32.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    The footer revision identifier changes from v3.7.1 to v3.7.2. The page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-18T12:42:42.000Z thumbnail image
  5. Check
    34 days ago
    Change Detected
    Summary
    The footer’s site revision identifier was updated from v3.7.0 to v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-11T14:15:29.000Z thumbnail image
  6. Check
    55 days ago
    Change Detected
    Summary
    The study record page now shows a 403 Forbidden error, indicating access is blocked. The additions include the HTML structure of a 403 page (title, header, and footer) rather than substantive study details.
    Difference
    21%
    Check dated 2026-09-20T20:25:41.000Z thumbnail image

Stay in the know with updates to Flotetuzumab in PIF/ER AML Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Flotetuzumab in PIF/ER AML Clinical Trial page.